JP2019524822A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524822A5 JP2019524822A5 JP2019507819A JP2019507819A JP2019524822A5 JP 2019524822 A5 JP2019524822 A5 JP 2019524822A5 JP 2019507819 A JP2019507819 A JP 2019507819A JP 2019507819 A JP2019507819 A JP 2019507819A JP 2019524822 A5 JP2019524822 A5 JP 2019524822A5
- Authority
- JP
- Japan
- Prior art keywords
- leucine
- acetyl
- pharmaceutically acceptable
- acceptable salt
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960000669 acetylleucine Drugs 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 19
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 claims 18
- 230000004770 neurodegeneration Effects 0.000 claims 15
- 208000015122 neurodegenerative disease Diseases 0.000 claims 15
- VVVBJVYNTROLEY-NRFANRHFSA-N (2S)-2-(hexadecylamino)-4-methylpentanoic acid Chemical compound C(CCCCCCCCCCCCCCC)N[C@@H](CC(C)C)C(=O)O VVVBJVYNTROLEY-NRFANRHFSA-N 0.000 claims 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 5
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 230000002068 genetic effect Effects 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 claims 1
- WXNXCEHXYPACJF-UHFFFAOYSA-N N-acetyl-leucine Chemical compound CC(C)CC(C(O)=O)NC(C)=O WXNXCEHXYPACJF-UHFFFAOYSA-N 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 210000000744 eyelid Anatomy 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 230000002132 lysosomal effect Effects 0.000 claims 1
- 230000000324 neuroprotective effect Effects 0.000 claims 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 230000002123 temporal effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021164793A JP7833272B2 (ja) | 2016-08-11 | 2021-10-06 | 神経変性疾患のための治療薬 |
| JP2023146465A JP2023175762A (ja) | 2016-08-11 | 2023-09-08 | 神経変性疾患のための治療薬 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1613829.9A GB201613829D0 (en) | 2016-08-11 | 2016-08-11 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| GB1613829.9 | 2016-08-11 | ||
| GBGB1702551.1A GB201702551D0 (en) | 2017-02-16 | 2017-02-16 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| GB1702551.1 | 2017-02-16 | ||
| GBGB1705766.2A GB201705766D0 (en) | 2017-04-10 | 2017-04-10 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| GB1705766.2 | 2017-04-10 | ||
| GBGB1706867.7A GB201706867D0 (en) | 2017-04-28 | 2017-04-28 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| GB1706867.7 | 2017-04-28 | ||
| PCT/IB2017/054929 WO2018029658A1 (en) | 2016-08-11 | 2017-08-11 | Therapeutic agents for neurodegenerative diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021164793A Division JP7833272B2 (ja) | 2016-08-11 | 2021-10-06 | 神経変性疾患のための治療薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524822A JP2019524822A (ja) | 2019-09-05 |
| JP2019524822A5 true JP2019524822A5 (https=) | 2020-09-17 |
| JP6957602B2 JP6957602B2 (ja) | 2021-11-02 |
Family
ID=59859424
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019507819A Active JP6957602B2 (ja) | 2016-08-11 | 2017-08-11 | 神経変性疾患のための治療薬 |
| JP2021164793A Active JP7833272B2 (ja) | 2016-08-11 | 2021-10-06 | 神経変性疾患のための治療薬 |
| JP2023146465A Pending JP2023175762A (ja) | 2016-08-11 | 2023-09-08 | 神経変性疾患のための治療薬 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021164793A Active JP7833272B2 (ja) | 2016-08-11 | 2021-10-06 | 神経変性疾患のための治療薬 |
| JP2023146465A Pending JP2023175762A (ja) | 2016-08-11 | 2023-09-08 | 神経変性疾患のための治療薬 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US12144792B2 (https=) |
| EP (3) | EP4467195A3 (https=) |
| JP (3) | JP6957602B2 (https=) |
| KR (4) | KR20250042197A (https=) |
| CN (4) | CN109789114A (https=) |
| AU (2) | AU2017308865B2 (https=) |
| BR (1) | BR112019002730A2 (https=) |
| CA (1) | CA3033564A1 (https=) |
| CY (1) | CY1121930T1 (https=) |
| DK (1) | DK3416631T3 (https=) |
| ES (1) | ES2733677T3 (https=) |
| HR (1) | HRP20191055T1 (https=) |
| HU (1) | HUE045043T2 (https=) |
| IL (3) | IL310799A (https=) |
| LT (1) | LT3416631T (https=) |
| MA (2) | MA47521A (https=) |
| MD (1) | MD3416631T2 (https=) |
| ME (1) | ME03454B (https=) |
| MX (3) | MX383499B (https=) |
| NZ (2) | NZ750421A (https=) |
| PL (1) | PL3416631T3 (https=) |
| PT (1) | PT3416631T (https=) |
| RS (1) | RS59048B1 (https=) |
| RU (1) | RU2756519C2 (https=) |
| SG (1) | SG11201901063SA (https=) |
| SI (1) | SI3416631T1 (https=) |
| SM (1) | SMT201900370T1 (https=) |
| TN (1) | TN2019000033A1 (https=) |
| WO (1) | WO2018029658A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10219815B2 (en) | 2005-09-22 | 2019-03-05 | The Regents Of The University Of Michigan | Histotripsy for thrombolysis |
| WO2016210133A1 (en) | 2015-06-24 | 2016-12-29 | The Regents Of The Universtiy Of Michigan | Histotripsy therapy systems and methods for the treatment of brain tissue |
| WO2018029658A1 (en) | 2016-08-11 | 2018-02-15 | Intrabio Limited | Therapeutic agents for neurodegenerative diseases |
| NZ750391A (en) | 2016-08-11 | 2026-03-27 | Intrabio Ltd | Pharmaceutical compositions and uses directed to lysosomal storage disorders |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| LT3697399T (lt) * | 2017-10-18 | 2026-01-12 | Intrabio Ltd | Terapiniai agentai, skirti panaudoti gydant neramių kojų sindromą |
| JP7337081B2 (ja) * | 2018-02-15 | 2023-09-01 | イントラバイオ リミティド | レストレスレッグズ症候群を治療するための治療薬 |
| JP2022510654A (ja) | 2018-11-28 | 2022-01-27 | ヒストソニックス，インコーポレーテッド | 組織破砕システムおよび方法 |
| JP7471298B2 (ja) * | 2018-12-06 | 2024-04-19 | イントラビオ エルティーディー | アセチル－ロイシンの重水素化類似体 |
| WO2020178721A1 (en) | 2019-03-02 | 2020-09-10 | Intrabio Ltd. | Leucine, acetyl leucine, and related analogs for treating disease |
| US20220346699A1 (en) * | 2019-09-17 | 2022-11-03 | Hoffmann-La Roche Inc. | Improvements in Personalized Healthcare for Patients with Movement Disorders |
| US20230051742A1 (en) * | 2020-01-13 | 2023-02-16 | Intrabio Ltd. | Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers |
| JP2023526517A (ja) * | 2020-05-22 | 2023-06-21 | イントラビオ エルティーディー | 運動失調症を治療するためのアセチルロイシンと４－アミノピリジン又はアセタゾラミドとの組合せ |
| WO2022264037A1 (en) * | 2021-06-14 | 2022-12-22 | Intrabio Ltd. | Branched-chain amino acid derivatives to treat disease |
| EP4608504A1 (en) | 2022-10-28 | 2025-09-03 | Histosonics, Inc. | Histotripsy systems and methods |
| KR20260003742A (ko) | 2023-04-20 | 2026-01-07 | 히스토소닉스, 인크. | 치료 계획 및 요법을 위한 사용자 인터페이스들 및 작업 흐름들을 포함하는 히스토트립시 시스템들 및 연관된 방법들 |
| WO2025151578A1 (en) * | 2024-01-12 | 2025-07-17 | Intrabio Inc. | N-acetyl-leucine for use in the treatment of prodromal alpha-synucleinopathies |
| WO2025163129A1 (en) * | 2024-02-01 | 2025-08-07 | Intrabio Ltd. | Acetyl-leucine for treating parkinson´s disease |
| WO2025166100A1 (en) | 2024-02-02 | 2025-08-07 | SynGAP Research Fund | Compositions and methods for treating neurodevelopmental disorders |
| WO2025175092A1 (en) * | 2024-02-14 | 2025-08-21 | Intrabio Inc. | Acetyl leucine for treating syngap1-related disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| US20050222209A1 (en) * | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| EP2932958A1 (en) | 2007-02-22 | 2015-10-21 | Beiersdorf AG | Cosmetic and pharmaceutical applications of n-acetylhydroxyproline |
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| TN2010000566A1 (en) | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| AU2014342624A1 (en) * | 2013-10-28 | 2016-06-02 | Naurex, Inc. | NMDA receptor modulators and prodrugs, salts, and uses thereof |
| US10905670B2 (en) | 2016-04-19 | 2021-02-02 | Intrabio Ltd. | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
| WO2018029658A1 (en) | 2016-08-11 | 2018-02-15 | Intrabio Limited | Therapeutic agents for neurodegenerative diseases |
-
2017
- 2017-08-11 WO PCT/IB2017/054929 patent/WO2018029658A1/en not_active Ceased
- 2017-08-11 PT PT17767934T patent/PT3416631T/pt unknown
- 2017-08-11 PL PL17767934T patent/PL3416631T3/pl unknown
- 2017-08-11 JP JP2019507819A patent/JP6957602B2/ja active Active
- 2017-08-11 CA CA3033564A patent/CA3033564A1/en active Pending
- 2017-08-11 NZ NZ750421A patent/NZ750421A/en unknown
- 2017-08-11 SM SM20190370T patent/SMT201900370T1/it unknown
- 2017-08-11 HU HUE17767934A patent/HUE045043T2/hu unknown
- 2017-08-11 AU AU2017308865A patent/AU2017308865B2/en active Active
- 2017-08-11 KR KR1020257008819A patent/KR20250042197A/ko active Pending
- 2017-08-11 LT LTEP17767934.7T patent/LT3416631T/lt unknown
- 2017-08-11 EP EP24191483.7A patent/EP4467195A3/en active Pending
- 2017-08-11 SI SI201730071T patent/SI3416631T1/sl unknown
- 2017-08-11 SG SG11201901063SA patent/SG11201901063SA/en unknown
- 2017-08-11 CN CN201780059708.6A patent/CN109789114A/zh active Pending
- 2017-08-11 IL IL310799A patent/IL310799A/en unknown
- 2017-08-11 CN CN202310627214.0A patent/CN116459244A/zh active Pending
- 2017-08-11 MA MA047521A patent/MA47521A/fr unknown
- 2017-08-11 IL IL264641A patent/IL264641B2/en unknown
- 2017-08-11 EP EP17767934.7A patent/EP3416631B1/en active Active
- 2017-08-11 CN CN202511449973.8A patent/CN121081445A/zh active Pending
- 2017-08-11 NZ NZ790893A patent/NZ790893A/en unknown
- 2017-08-11 CN CN202310629563.6A patent/CN116492328A/zh active Pending
- 2017-08-11 KR KR1020247014635A patent/KR102785448B1/ko active Active
- 2017-08-11 RU RU2019106506A patent/RU2756519C2/ru active
- 2017-08-11 ES ES17767934T patent/ES2733677T3/es active Active
- 2017-08-11 KR KR1020197007032A patent/KR102413756B1/ko active Active
- 2017-08-11 DK DK17767934.7T patent/DK3416631T3/da active
- 2017-08-11 IL IL310801A patent/IL310801A/en unknown
- 2017-08-11 BR BR112019002730-0A patent/BR112019002730A2/pt not_active Application Discontinuation
- 2017-08-11 KR KR1020227021012A patent/KR20220093385A/ko not_active Ceased
- 2017-08-11 US US16/324,353 patent/US12144792B2/en active Active
- 2017-08-11 MX MX2019001575A patent/MX383499B/es unknown
- 2017-08-11 TN TNP/2019/000033A patent/TN2019000033A1/fr unknown
- 2017-08-11 MA MA43828A patent/MA43828B1/fr unknown
- 2017-08-11 RS RS20190801A patent/RS59048B1/sr unknown
- 2017-08-11 MD MDE20190027T patent/MD3416631T2/ro unknown
- 2017-08-11 EP EP19174007.5A patent/EP3583940A1/en active Pending
- 2017-08-11 HR HRP20191055TT patent/HRP20191055T1/hr unknown
- 2017-08-11 ME MEP-2019-169A patent/ME03454B/me unknown
-
2019
- 2019-02-07 MX MX2021006901A patent/MX2021006901A/es unknown
- 2019-07-16 CY CY20191100759T patent/CY1121930T1/el unknown
-
2021
- 2021-10-06 JP JP2021164793A patent/JP7833272B2/ja active Active
-
2023
- 2023-03-15 US US18/183,972 patent/US20230210799A1/en active Pending
- 2023-04-05 AU AU2023202121A patent/AU2023202121B2/en active Active
- 2023-09-08 JP JP2023146465A patent/JP2023175762A/ja active Pending
-
2024
- 2024-01-12 US US18/411,512 patent/US20240189267A1/en active Pending
- 2024-04-11 MX MX2024004439A patent/MX2024004439A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524822A5 (https=) | ||
| HRP20191055T1 (hr) | Terapeutska sredstva za neurodegenerativne bolesti | |
| JOP20230235A1 (ar) | عقاقير أولية جديدة من الكاتيكولامين للاستخدام في علاج مرض باركنسون | |
| JP2016535786A5 (https=) | ||
| ZA202001057B (en) | Inhibiting ubiquitin specific peptidase 30 | |
| JP2020503323A5 (https=) | ||
| JP2019524865A5 (https=) | ||
| WO2018060732A3 (en) | Compositions and methods for treating seizure disorders | |
| EA201992607A1 (ru) | Твердые формы берберина урсодезоксихолата, их композиции и способы | |
| ME02390B (me) | Inhibitori beta sekretaze | |
| HK1198619A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| EP3672587A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | |
| JP2019529541A5 (https=) | ||
| JP2015510916A5 (https=) | ||
| JP2016512817A5 (https=) | ||
| JP2016537338A5 (https=) | ||
| HRP20220029T1 (hr) | Supstituirani derivati ksantina | |
| JP2016509030A5 (https=) | ||
| HRP20210361T1 (hr) | Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja | |
| WO2015047982A3 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| WO2015013187A8 (en) | Ppar-sparing compounds for the treatment of metabolic diseases | |
| JP2018502163A5 (https=) | ||
| JP2016537432A5 (https=) | ||
| JP2016523969A5 (https=) | ||
| RU2020115710A (ru) | Терапевтические агенты для нейродегенеративных заболеваний |